

TasAlk to Manufacture Zelira's Insomnia and HOPE™ products

26 May 2020

- **Agreement with Tasmanian Alkaloids for the exclusive manufacture of Zelira's Insomnia and HOPE™ products in the Asian Pacific region**
- **Secures access to GMP-certified manufacture of Zelira's medicinal cannabinoid products**
- **TasAlk is a world-leader in manufacture and export of controlled plant-derived medicinal products**
- **TasAlk holds all relevant licenses to supply into APAC region markets**
- **Australian launch of Insomnia and HOPE™ medicinal cannabis products on-track for Q3 2020, which would transform Zelira into a fully commercial, revenue generating company in the US and Australia**

Zelira Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF): a leading medicinal cannabis company is pleased to announce it has signed a commercial supply agreement with Tasmanian Alkaloids Pty Ltd (TasAlk) to manufacture Zelira's proprietary Insomnia and HOPE™ medicinal cannabis formulations.

TasAlk is a global leader in the extraction and purification of high-value plant-derived products for the pharmaceutical industry and has added medicinal cannabis products and services to its portfolio.

Under the agreement, TasAlk will have exclusive rights to manufacture Zelira's Insomnia and HOPE™ formulations initially in the Asia Pacific (APAC) region for the first year and then on a semi-exclusive basis for the subsequent three years. In Australia, all products will be supplied to patients under the Australian Government TGA Special Access Scheme (SAS).

The agreement with TasAlk ensures that Zelira remains on-track to launch both the Insomnia and HOPE™ products in Australia in Q3 2020. Once launched, these efforts will transform Zelira into a fully commercial, revenue generating company in both the US and Australia.

The manufacture and analytical method for the Insomnia product is under technical transfer to TasAlk from a European GMP manufacturer that supplied material for the recent insomnia clinical trial. This will ensure TasAlk can achieve rapid commercial-scale production while guaranteeing consistent high-quality products.

Zelira's experience with the launched HOPE™ product line in the USA market is expected to accelerate the manufacture of the HOPE product by TasAlk and represents a major stepping-stone to commercialising the HOPE™ formulations in ex-US markets.

Zelira's Managing Director ex-USA, Dr Richard Hopkins, commented "We're delighted to be partnering with TasAlk, one of the world's leading manufacturers of pharmaceutical-grade plant-derived medicines. The agreement reaffirms our commitment to bring our clinically validated products to market in 2020."

TasAlk CEO, Dr Ross Murdoch said, "This agreement aligns with our business model and expertise in providing clinical trial materials. It provides the foundation for a long-term partnership that has potential to open up supply opportunities in major world markets for Zelira's products."

This announcement has been authorised by the Board.

Richard Hopkins
Managing Director

About Zelira's HOPE and Insomnia Products

In a world first, Zelira recently announced that its proprietary Insomnia formulation, ZTL-101, had successfully met its primary and secondary clinical endpoints for safety and efficacy in a Phase 1a/2b clinical trial targeting patients with chronic insomnia. The trial was conducted at the University of Western Australia Sleep Centre, led by Professor Peter Eastwood, under the regulatory auspices of the Australian TGA.

The HOPE™ franchise was developed to address patient symptoms associated with Autism Spectrum Disorder. In the United States, the franchise was launched successfully in Pennsylvania in May 2019 under Ilera Healthcare, which holds the license for the state. HOPE™ has also been licensed to Advance Biomedics LLC in Louisiana for launch and availability to patients throughout Louisiana.

About Zelira Therapeutics (www.zeliratx.com)

Zelira Therapeutics Ltd is a leading global therapeutic medicinal cannabis company with access to the world's largest and fastest growing cannabis markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020. The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions.

The Company is undertaking product development programs targeting specific conditions (e.g. HOPE™) and human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the USA.

The Company conducts this work in partnership with world-leading researchers and organizations including Complutense University in Madrid, Spain; Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.

The Company has developed two proprietary formulations (HOPE™) already launched and generating revenues in Pennsylvania, has laboratory capabilities to develop formulations in Pennsylvania and Louisiana with ability to conduct clinical trials and is establishing a national footprint across the US for the licensing of its products.

About Tasmanian Alkaloids (www.tasalk.com.au)

Tasmanian Alkaloids Pty Ltd is a globally focused innovative research and manufacturing company based in Tasmania, Australia. The company is fully integrated from field and factory to the finished goods, employing highly skilled scientifically and technically qualified employees. For over 40 years TasAlk has developed and cultivated high-yielding agricultural raw materials for the extraction and purification of high-value plant-derived products for the pharmaceutical industry and includes businesses focused on natural alkaloid and cannabinoid based products.

Address

Level 26
140 St Georges Terrace
Perth WA 6000
AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeliratx.com
W: www.zeliratx.com
ACN 103 782 378

Tickers

Australia (ASX): ZLD
USA (OTCQB): ZLDAF

Australia Contacts:

Dr Richard Hopkins
Managing Director & CEO, Ex USA
+61 405 656 868
rhopkins@zeliratx.com
Level 26, 140 St Georges Terrace
Perth WA 6000
AUSTRALIA

Monsoon Communications

Rudi Michelson
+61 3 9620 3333
rudim@monsoon.com

U.S. Contacts:

Dr Oludare Odumosu
Managing Director & CEO, USA
+1 909 855 0675
oodumosu@zeliratx.com
3553 West Chester Pike #110
Newtown Square PA 19073
UNITED STATES OF AMERICA

GVM Communications, Inc.

Gia Morón
+1 347 678 8079
gia@gvmcommsinc.com